Acute gastric dilation associated with the use of semaglutide, a GLP-1 analogue

Gastroenterol Hepatol. 2022 Apr:45 Suppl 1:125-126. doi: 10.1016/j.gastrohep.2020.11.021. Epub 2021 Feb 2.

[Article in English, Spanish]

Authors

Patricia Sanz Segura¹, Yolanda Arguedas Lázaro², Sonia Mostacero Tapia², Juan Manuel Nerín de la Puerta², Juan José Sebastián Domingo²

Affiliations

¹ Servicio de Aparato Digestivo, Hospital Royo Villanova, Zaragoza, España. Electronic address: patricia.sanz.segura@gmail.com.
² Servicio de Aparato Digestivo, Hospital Royo Villanova, Zaragoza, España.

PMID: 33545249
DOI: 10.1016/j.gastrohep.2020.11.021

No abstract available

Publication types

Case Reports

MeSH terms

Diabetes Mellitus, Type 2* / complications
Diabetes Mellitus, Type 2* / drug therapy
Gastric Dilatation* / chemically induced
Gastric Dilatation* / complications
Glucagon-Like Peptide 1 / adverse effects
Glucagon-Like Peptides
Humans
Hypoglycemic Agents / adverse effects

Substances

Hypoglycemic Agents
semaglutide
Glucagon-Like Peptides
Glucagon-Like Peptide 1